Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Morningside Ventures
Deal Size: $196.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 14, 2021
Funding will support initiation and finalization of Phase 3 development of obicetrapib, a potent ApoB and LDL-c lowering small molecule drug, intended for patients not well-controlled on statins.